News: Prostate Cancer

A five-year follow-up study of U.S. men who received prostate cancer treatment is creating a road map for future patients to clarify expectations and enable men to make informed choices about care.

Some of the nation’s leading genitourinary cancer physicians will speak about the latest advances in care at an OncLive State of the Science Summit held in collaboration with Vanderbilt-Ingram Cancer Center.

An analysis of more than 140,000 people of European ancestry has identified blood protein biomarkers associated with prostate cancer risk.

Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.

Vanderbilt collaborators focused on minimally invasive prostate surgery are developing an endoscopic robotic system with two-handed dexterity at a much smaller scale than existing options.

Austin Kirschner, MD, PhD, and colleagues have studied the mechanism of radiation sensitization for enzalutamide using multiple models of human prostate cancer.

The Vanderbilt Institute for Surgery and Engineering (VISE) team of Robert Webster III, PhD, and Duke Herrell, MD, have received a $2.2 million grant from the National Institutes of Health to develop a new surgical robot for endoscopic transurethral prostatectomy.

Prostate cancer patients in Nashville and Los Angeles are benefiting from a computer-based decision aid that implements the latest study results to tailor treatment options to an individual’s quality-of-life priorities.

Vanderbilt urologic surgeons are offering an alternative therapy for prostate cancer patients considered to be low-to-intermediate risk, a middle ground between active surveillance and aggressive therapy.

Making sense of the updated guidelines for prostate cancer screening.